{
  "id": 15432466,
  "title": "Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?",
  "url": "https://urgent.news/2026/10/18/novo-trades-at-less-than-12-times-earnings-is-this-the-buying-15432466",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T14:20:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/novo-trades-less-12-times-earnings-buying-opportunity-decade"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsNovo has experienced several setbacks, especially in its core therapeutic area.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?",
        "url": "https://urgent.news/2026/10/18/novo-trades-at-less-than-12-times-earnings-is-this-the-buying",
        "published": "2026-10-18T14:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}